← Back to Search

Therapy and Peer Support for Opioid Use Disorder

N/A

Waitlist Available

Led By David S. Festinger, Ph.D.

Research Sponsored by Philadelphia College of Osteopathic Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults (≥18 years)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial is investigating different types of psychosocial interventions to help people with opioid use disorder, with the goal of finding which interventions work best for different types of patients.

Who is the study for?

This trial is for adults over 18 with opioid use disorder who are eligible and agree to buprenorphine treatment. They must be stable enough not to need inpatient care, able to give informed consent, and provide contact information. People intoxicated, cognitively impaired or psychiatrically unstable at the start are excluded but can join later if conditions improve.

What is being tested?

The study tests different psychosocial treatments alongside medication-assisted treatment (MAT) for opioid addiction. It aims to find out which psychosocial approaches work best for various patients rather than using a standard method for all.

What are the potential side effects?

While specific side effects of the psychosocial interventions aren't detailed, typical reactions might include emotional discomfort or stress due to therapy discussions. Buprenorphine may cause drowsiness, dizziness, constipation, or nausea.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Urinalysis-confirmed opioid use

Secondary study objectives

ED utilization

Multidimensional problem severity

Opioid overdose rates

+4 more

Other study objectives

Provider outcome: Job satisfaction and stress

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Active Control

Group I: Treatment as usualActive Control1 Intervention

Those randomized to treatment as usual will receive standard treatment from one of four FQHC sites.

Group II: Office based CBTActive Control1 Intervention

Those randomized to Cognitive Behavioral Treatment will receive cognitive behavioral treatment (CBT) along with standard treatment from the FQHC.

Group III: CRS/CPSActive Control1 Intervention

Those randomized to certified recovery specialist(CRS)/peer support specialist(CPS) will receive a CRS/CPS along with standard treatment from the FQHC.

Group IV: CBT+CRS/CPSActive Control1 Intervention

Those randomized to MAT+ office-based CBT will receive office-based buprenorphine treatment along with office-based CBT and a CRS.

0 / 1Eligibility criteria met